Conference Call Scheduled for Wednesday, February 28, 2018 at 4:30pm
ET
NEWARK, Calif.--(BUSINESS WIRE)--
Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company
developing neuromodulators for use in treating aesthetic and underserved
therapeutic conditions, today announced that the company will release
fourth quarter and full year 2017 financial results on Wednesday,
February 28, 2018 after the close of market. Revance will host a
corresponding conference call and a live webcast at 1:30pm PT/4:30pm ET
on the same day to discuss the results and provide a business and
pipeline update.
Individuals interested in listening to the conference call may do so by
dialing (855) 453-3827 for domestic callers, or (484) 756-4301 for
international callers and reference conference ID: 5054928; or from the
webcast link in the investor relations section of the company's website
at: www.revance.com.
A replay of the call will be available beginning February 28, 2018 at
4:30pm PT/7:30pm ET to March 1, 2018 at 4:30pm PT/7:30pm ET. To access
the replay, dial (855) 859-2056 or (404) 537-3406 and reference
conference ID: 5054928. The webcast will be available in the investor
relations section on the company's website for 30 days following the
completion of the call.
About Revance Therapeutics, Inc.
Revance Therapeutics is a biotechnology company developing
neuromodulators for use in treating aesthetic and underserved
therapeutic conditions, including muscle movement disorders and pain.
The company's lead drug candidate, DaxibotulinumtoxinA for Injection
(RT002), is currently in development for the treatment of glabellar
lines, cervical dystonia and plantar fasciitis, with the potential to be
the first long-acting neuromodulator. Revance has developed a
proprietary, stabilizing excipient peptide technology designed to create
novel, differentiated therapies. The company has a comprehensive
pipeline based upon its peptide technology, including injectable and
topical formulations of daxibotulinumtoxinA. More information on Revance
may be found at www.revance.com.
"Revance Therapeutics" and the Revance logo are registered trademarks of
Revance Therapeutics, Inc.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180222006367/en/
INVESTORS
Revance Therapeutics, Inc.:
Jeanie Herbert,
714-325-3584
jherbert@revance.com
or
Burns
McClellan, Inc.:
Ami Bavishi, 212-213-0006
abavishi@burnsmc.com
or
MEDIA
General
Media:
TOGORUN:
Mariann Caprino, 917-242-1087
m.caprino@togorun.com
or
Trade
Media:
Nadine Tosk, 504-453-8344
nadinepr@gmail.com
Source: Revance Therapeutics, Inc.
News Provided by Acquire Media
